MicroRNA expression and functional profiles of osteosarcoma

Oncology (Switzerland)

Volumn 86, Issue 2, 2014, Pages 94-103

  Kobayashi, Eisuke ^a,b   Satow, Reiko ^a   Ono, Masaya ^a   Masuda, Mari ^a   Honda, Kazufumi ^a   Sakuma, Tomohiro ^c   Kawai, Akira ^d   Morioka, Hideo ^b   Toyama, Yoshiaki ^b   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c BioBusiness Group   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Microarray; MicroRNA; Osteosarcoma; Proteomics

Indexed keywords

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP47 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICRORNAS; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; RNA INTERFERENCE; TRANSCRIPTOME; VIMENTIN; YOUNG ADULT;

MICRORNA; ONCOPROTEIN; SERPIN H1; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VIMENTIN;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHILD; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LET 7 GENE; LET 7A GENE; LET 7B GENE; LET 7F GENE; LET 7G GENE; LET 7I GENE; MALE; MICROARRAY ANALYSIS; MULTIGENE FAMILY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

EID: 84892734202     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000357408     Document Type: Article

References (42)

1. Uribe-Botero G, Russell WO, Sutow WW, Martin RG: Primary osteosarcoma of bone: clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 1977; 67: 427-435.
2. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
3. Clark JC, Dass CR, Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 281-297.
4. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and highdose methotrexate. J Clin Oncol 2005; 23: 2004-2011.
5. Ambros V: The functions of animal micro RNAs. Nature 2004; 431: 350-355.
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
7. Negrini M, Ferracin M, Sabbioni S, Croce CM: MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007; 120: 1833-1840.
8. Berezikov E, Guryev V, van de Belt J, et al: Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120: 21-24.
9. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
10. Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some micro RNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
11. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
12. Song B, Wang Y, Xi Y, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-4074.
13. Song B, Wang Y, Titmus MA, et al: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010; 9: 96.
14. Ziyan W, Shuhua Y, Xiufang W, Xiaoyun L: MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol 2011; 28: 1469-1474.
15. He C, Xiong J, Xu X, et al: Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009; 388: 35-40.
16. Kobayashi E, Masuda M, Nakayama R, et al: Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 2010; 9: 535-544.
17. Fukao T, Fukuda Y, Kiga K, et al: An evolutionarily conserved mechanism for micro RNA-223 expression revealed by microRNA gene profiling. Cell 2007; 129: 617-631.
18. Huang L, Shitashige M, Satow R, et al: Functional interaction of DNA topoisomerase IIα with the β-catenin and T-cell factor-4 complex. Gastroenterology 2007; 133: 1569-1578.
19. Yamaguchi U, Honda K, Satow R, et al: Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009; 100: 2268-2274.
20. Masuda T, Tomita M, Ishihama Y: Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res 2008; 7: 731-740.
21. Ono M, Matsubara J, Honda K, et al: Prolyl 4-hydroxylation of α-fibrinogen: a novel protein modification revealed by plasma proteomics. J Biol Chem 2009; 284: 29041-29049.
22. Ono M, Shitashige M, Honda K, et al: Labelfree quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 1338-1347.
23. Idogawa M, Masutani M, Shitashige M, et al: Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate β-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 2007; 67: 911-918.
24. Osada H, Takahashi T: let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011; 102: 9-17.
25. Lewis BP, Shih IH, Jones-Rhoades MW, et al: Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798.
26. Krek A, Grun D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
27. Negishi A, Ono M, Handa Y, et al: Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci 2009; 100: 514-519.
28. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
29. Volinia S, Calin GA, Liu CG, et al: A micro RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
30. Subramanian S, Lui WO, Lee CH, et al: MicroRNA expression signature of human sarcomas. Oncogene 2008; 27: 2015-2026.
31. Sarver AL, Phalak R, Thayanithy V, Subramanian S: S-MED: sarcoma microRNA expression database. Lab Invest 2010; 90: 753-761.
32. Roush S, Slack FJ: The let-7 family of micro RNAs. Trends Cell Biol 2008; 18: 505-516.
33. Boyerinas B, Park SM, Hau A, et al: The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010; 17:F19-F36.
34. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 micro RNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
35. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21: 1025-1030.
36. Baek D, Villen J, Shin C, et al: The impact of microRNAs on protein output. Nature 2008; 455: 64-71.
37. Selbach M, Schwanhausser B, Thierfelder N, et al: Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58-63.
38. Matsubara J, Ono M, Negishi A, et al: Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol 2009; 27: 2261-2268.
39. Matsubara J, Ono M, Honda K, et al: Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics 2010; 9: 695-704.
40. Lian N, Wang W, Li L, et al: Vimentin inhibits ATF4-mediated osteocalcin transcription and osteoblast differentiation. J Biol Chem 2009; 284: 30518-30525.
41. Ragg H: The role of serpins in the surveillance of the secretory pathway. Cell Mol Life Sci 2007; 64: 2763-2770.
42. Nagai N, Hosokawa M, Itohara S, et al: Embryonic lethality of molecular chaperone Hsp47 knockout mice is associated with defects in collagen biosynthesis. J Cell Biol 2000; 150: 1499-1506.